Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials

Ipilimumab is a fully human, monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 to potentiate an antitumor T-cell response. This agent improved overall survival in a phase III trial in previously treated patients with advanced melanoma. Because the mechanism of action for ipilimumab is...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Wolchok, Jedd D., Weber, Jeffrey S., Hamid, Omid, Lebbé, Celeste, Maio, Michele, Schadendorf, Dirk, de Pril, Veerle, Heller, Kevin, Chen, Tai-Tsang, Ibrahim, Ramy, Hoos, Axel, O'Day, Steven J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Academy of Cancer Immunology 2010
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2964017/
https://ncbi.nlm.nih.gov/pubmed/20957980
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller